arrow
G

Gabriele Schaefer

genentech, inc.
H指数:27
被引数:3,404

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity

肿瘤靶向双特异性抗体可有效抑制致癌通路同时最小化毒性

2026-05-220
OA
Characterization of an anti-STEAP1 T-cell dependent bispecific antibody for the treatment of prostate cancer and associated toxicity in cynomolgus monkeys

抗STEAP1 T细胞依赖性双特异性抗体在前列腺癌治疗中的应用及其在食蟹猴中的相关性毒性表征

2026-03-010
PRE
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

在1b期研究中,结合PARP和MEK抑制,有或没有anti-PD-L1,对BRCA野生型,铂敏感,复发性卵巢癌患者的主要结果和特征

CANCER
IF5.1
2024-01-301
OAAI
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor
2016-09-1232
PREAI
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study (vol 58, pg 8877, 2015)
2016-03-110
OAAI
Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR
2015-12-2137
OAAI
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
2015-11-1252
PREAI
Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation
2014-11-2072
OAAI
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

曲妥珠单抗Emtansine和帕妥珠单抗双重靶向HER2-Positive: 神经调节素阻断在联合治疗抗肿瘤反应中的关键作用

2014-01-16168
OAAI